EBV‐Positive Diffuse Large B‐Cell Lymphoma (DLBCL): An Assessment and a Roadmap
Journal of Medical Virology · 2025-12 · 97 (12)
DOI: 10.1002/jmv.70722 ↗Abstract
ABSTRACT Diffuse large B‐cell Lymphoma (DLBCL) is the most common lymphoma subtype worldwide. The Epstein Barr Virus (EBV) is a human DNA virus associated with a spectrum of human malignancies. EBV is detected in 5% to 15% of DLBCL tumors with no history of immunosuppression. Early reports of EBV‐positive DLBCL suggested distinct clinical presentation, unique tumor microenvironment (TME), and inferior survival compared to EBV‐negative DLBCL. A better definition of EBV‐positive cases treated with modern chemo‐immunotherapy has recently improved our understanding of this entity. Recent studies have provided initial insights into the distinct mutational landscape and immune microenvironment of EBV‐positive DLBCL and identified EBV as an independent prognostic biomarker in DLBCL. Despite these advances, fundamental questions remain. We provide an overview of emerging clinical and molecular aspects of EBV‐positive DLBCL and discuss recent efforts to develop EBV‐targeting therapies. We also discuss key research questions in EBV‐positive DLBCL.
EUVIMED